ClinicalTrials.gg
CompletedNCT00053638Updated Oct 4, 2010

A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy

A Phase 3 interventional study of efavirenz and tenofovir in HIV Infection, sponsored by GlaxoSmithKline. Completed at 58 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-10-04.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
345
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies testing efavirenz in HIV Infections — none open to participants now, none under way, none of them phase 3. efavirenz · HIV Infections.

Enrollment
18th of 96
345 · median 75
Started
2003
with 1 other
Phase 3
28 of 101
none open now
Registered
34th of 101
by date
Lead sponsor
3 of 101
GlaxoSmithKline

Among the 101 studies testing efavirenz in HIV Infections, this one is the 18th largest by enrollment of the 96 interventional ones that give a count, is one of 2 that started in 2003, is one of 28 in phase 3, and was the 34th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 101 studies testing efavirenz in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About efavirenz

efavirenz: first FDA approval 1998 (SUSTIVA), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 101 studies testing efavirenz in HIV Infections as a file.
02

Study summary

This is a 48-week study to evaluate the safety and efficacy of a new tablet formulation containing two FDA-approved drugs in HIV-infected patients who have not received prior therapy. This tablet will be taken with one of two FDA-approved drugs as a once-daily regimen. Study physicians will evaluate subjects to determine if they have certain medical conditions, laboratory test values, medication use, or drug allergies that would exclude them from the study.

03

Conditions studied

  • HIV Infection

Browse trials for

Keywords

  • HIV-1 Efavirenz Tenofovir
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be able to provide .
  • Have documented -1 infection.
  • Have not received more than 14 days of prior treatment with antiretroviral drugs.
  • Meet laboratory test criteria.
  • Women of must abstain from sexual intercourse or use acceptable .
  • Must be able to take study medications as directed and complete all study visits and evaluations during the 48 week study.

Exclusion criteria

Exclusion criteria:

  • Enrolled in other treatment studies.
  • Pregnant or breastfeeding.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
345 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Viral load response at 48 weeks

    Time frame: 48 weeks

Secondary outcomes

  1. Safety and tolerability Viral load response at 24 weeks Change in T-cell count Resistance Pharmacokinetics

    Time frame: 48 weeks

07

Study locations

58 sites
  • GSK Investigational Site
    Phoenix, Arizona 85006, United States
  • GSK Investigational Site
    Fountain Valley, California 92708, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    San Francisco, California 94115-1931, United States
  • GSK Investigational Site
    Denver, Colorado 80205, United States
  • GSK Investigational Site
    Denver, Colorado 80220, United States
  • GSK Investigational Site
    Fort Collins, Colorado 80528, United States
  • GSK Investigational Site
    Washington, District of Columbia 20007-2113, United States
  • GSK Investigational Site
    Washington, District of Columbia 20009, United States
  • GSK Investigational Site
    Washington, District of Columbia 20036, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33145, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Fort Myers, Florida 33901, United States
  • GSK Investigational Site
    Jacksonville, Florida 32206, United States
  • GSK Investigational Site
    Miami, Florida 33133, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    North Miami, Florida 33161, United States
  • GSK Investigational Site
    Orlando, Florida 32804, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Tampa, Florida 33602, United States
  • GSK Investigational Site
    Vero Beach, Florida 32960, United States
  • GSK Investigational Site
    Atlanta, Georgia 30309, United States
  • GSK Investigational Site
    Atlanta, Georgia 30339, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Chicago, Illinois 60657, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202 - 5124, United States
  • GSK Investigational Site
    Wichita, Kansas 67214, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70115, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70127-0800, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55404, United States
  • GSK Investigational Site
    Hillsborough, New Jersey 08844, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87131-0001, United States
  • GSK Investigational Site
    Albany, New York 12208, United States
  • GSK Investigational Site
    Buffalo, New York 14215, United States
  • GSK Investigational Site
    New York, New York 10011, United States
  • GSK Investigational Site
    New York, New York 10014, United States
  • GSK Investigational Site
    Stony Brook, New York 11794, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45267-0405, United States
  • GSK Investigational Site
    Portland, Oregon 97210, United States
  • GSK Investigational Site
    Portland, Oregon 97219, United States
  • GSK Investigational Site
    Hershey, Pennsylvania 17033, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19102, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Reading, Pennsylvania 19601, United States
  • GSK Investigational Site
    Providence, Rhode Island 02903, United States
  • GSK Investigational Site
    Columbia, South Carolina 29206-4713, United States
  • GSK Investigational Site
    Dallas, Texas 75208, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Tyler, Texas 75708, United States
  • GSK Investigational Site
    Hampton, Virginia 23666, United States
  • GSK Investigational Site
    Lynchburg, Virginia 24501, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
  • GSK Investigational Site
    Tacoma, Washington 98405, United States
  • GSK Investigational Site
    Green Bay, Wisconsin 54301, United States
08

References and documents

Publications

  • Underwood MR, Ross LL, Irlbeck DM, Gerondelis P, Rouse E, St Clair MH, Trinh L, Parkin N, Lanier E. Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1. J Infect Dis. 2009 Jan 1;199(1):84-8. doi: 10.1086/595296. PubMed 19032103 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Oct 2004 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2003
First posted
Feb 5, 2003
Start
Feb 2003
Primary completionActual
Oct 2004
CompletionActual
Oct 2004
Last update
Oct 4, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00053638
Lead sponsor
GlaxoSmithKline
First posted
Feb 5, 2003
Start date
Feb 2003
Primary completion
Oct 2004
Completion
Oct 2004
Last update
Oct 4, 2010

Study contacts

GSK Clinical Trials, MD
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efavirenz · Tenofovir

Start the discussion